Tenax Therapeutics
Signal active
Investment Firm
Overview
Tenax Therapeutics is a pharmaceutical company that focuses on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. Tenax Therapeutics develops novel dosing and formulations of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension. Imatinib, which acts on underlying cellular proliferative pathways linked to PAH, has the potential to be the first disease-modifying therapy for the disease.
Highlights
Founded
1967
Industry
Biotechnology
Employees
11-50
Investment
1
Lead Investment
0
Exits
undefined
Stages
N/A
Investor Type
N/A
Location
United States, North America
Contact Information
Social
Profile Resume
Tenax Therapeutics, established in 1967 and headquartered in United States, North America., specializes in investments across Education, EdTech, Universities. Their recent investments include Imperial College London. The highest investment round they participated in was $6.0M. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Tenax Therapeutics has made 1 investments. Their most recent investment was on Aug 06, 2014, when Imperial College London raised $500.0K.
investments
1
Diversity investments
0
Lead investments
0
Number of exits
undefined
Investments
1
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Aug 06, 2014 | Imperial College London | Education | 500.0K |
Exits
0
Funding Timeline
Funding rounds
1
Investors
9
Funds
0
Funding Rounds
1
Tenax Therapeutics has raised 1 rounds. Their latest funding was raised on Aug 06, 2014 from a Grant - Imperial College London round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Aug 06, 2014 | Grant - Imperial College London | - | 500.0K | - |
Investors
17
Tenax Therapeutics is funded by 17 investor(s). Vivo Capital and BVF Partners Kantor are the most recent investors.
| Investor Name | Lead Investor | Funding Round | Money Raised |
|---|---|---|---|
ADAR1 Capital Management | No | Post-IPO Equity - Tenax Therapeutics | 100.0M |
BVF Partners | Yes | Post-IPO Equity - Tenax Therapeutics | 100.0M |
| - | No | Post-IPO Equity - Tenax Therapeutics | 100.0M |
Vivo Capital | No | Post-IPO Equity - Tenax Therapeutics | 100.0M |
Vivo CapitalFund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.